Agastache rugosa leaf extract inhibits the iNOS expression in ROS 17/2.8 cells activated with TNF-α and IL-1β
- 78 Downloads
It has been suggested that nitric oxide (NO) derived from inducible nitric oxide synthase (iNOS) may act as a mediator of cytokine-induced effects on bone turn-over. NO is also recognized as an important factor in bone remodeling, i.e., participating in osteoblast apoptosis in an arthritic joint. The components ofAgastache rugosa are known to have many pharmacological activities. In the present study, we investigated the effects of Agastache rugosa leaf extract (ELAR) on NO production and the iNOS expression in ROS 17/2.8 cells activated by a mixture of inflammatory cytokines including TNF-α and lL-1². A preincubation with ELAR significantly and concentration-dependently reduced the expression of iNOS protein in ROS 17/2.8 cells activated with the cytokine mixture. Consequently, the NO production was also significantly reduced by ELAR with an IC50 of 0.75 mg/mL The inhibitory mechanism of iNOS induction by ELAR prevented the activation and translocation of NF-κB (p65) to the nucleus from the cytosol fraction. Furthermore, ELAR concentration-dependently reduced the cellular toxicity induced by sodium nitroprusside, an NO-donor. These results suggest that ELAR may be beneficial in NO-mediated inflammatory conditions such as osteoporosis.
Key wordsNitric oxide Osteoarthritis Bone turn-over Osteoblast Agastache rugosa
Unable to display preview. Download preview PDF.
- Armour, K. J., Armour, K. E., VanT Hof, R. J., Reid, D. M., Wei, X. Q., Liew, F. Y., and Ralston, S. H., Activation of the inducible nitric oxide synthase pathway contributes to inflammation induced osteoporosis by suppressing bone formation and causing osteoblast apoptosis.Arthritis Rheum., 44, 2790–2796 (2001).PubMedCrossRefGoogle Scholar
- Boileau, C., Martel-Pelletier, J., Moldovan, F., Jouzeau, J. Y., Netter, R., Manning, P. T., and Pelletier, J. P., Thein situ up- regulation of chondrocyte interleukin-1-converting enzyme and interleukin-18 levels in experimental osteoarthritis is mediated by nitric oxide.Arthritis Rheum., 46, 2637–2647 (2002).PubMedCrossRefGoogle Scholar
- Chae, H. J., Chae, S. W., Kang, J. S., Bang, B. G., Cho, S. B., Park, R. K., So, H. S., Kim, Y. K., Kim, H. M., and Kim, H. R., Dexamethasone suppresses tumor necrosis factor-alpha-induced apoptosis in osteoblasts: possible role for ceramide.Endocrinology, 141, 2904–2913 (2000a).PubMedCrossRefGoogle Scholar
- Hukkanen, M., Hughes, F. J., Buttery, L. D., Gross, S. S., Evans, T. J., Seddon, S., Riveros-Moreno, V., Macintyre, I., and Polak, J. M., Cytokine-stimulated expression of inducible nitric oxide synthase by mouse, rat, and human osteoblast-like cells and its functional role in osteoblast metabolic activity.Endocrinology, 136, 5445–5453 (1995).PubMedCrossRefGoogle Scholar
- Kang, Y. J., Koo, E. B., Lee, Y. S., Yun-Choi, H. S., and Chang, K. C., Prevention of the expression of inducible nitric oxide synthase by a novel positive inotropic agent, YS 49, in rat vascular smooth muscle and RAW 264.7 macrophages.Br. J. Pharmacol., 128, 357–364 (1999).PubMedCrossRefGoogle Scholar
- Kitajima, I., Nakajima, T., Imamura, T., Takasaki, I., Kawahara, K., Okano, T., Tokioka, T., Soejima, Y., Abeyama, K., and Maruyama, I., Induction of apoptosis in murine clonal osteoblasts expressed by human T-cell leukemia virus type I tax by NF-kappa B and TNF-alpha.J. Bone Miner. Res., 11, 200–210 (1996).PubMedCrossRefGoogle Scholar
- Lin, S. K., Kok, S. H., Kuo, M. Y., Lee, M. S., Wang, C. C., Lan, W. H., Hsiao, M., Goldring, S. R., and Hong, C. Y., Nitric oxide promotes infectious bone resorption by enhancing cytokin-stimulated interstitial collagenase synthesis in osteoblasts.J. Bone Miner. Res., 18, 39–46 (2003).PubMedCrossRefGoogle Scholar
- Pelletier, J. P., Fernandes J. C., Jovanovic, D. V., Reboul, P., and Martel-Pelletier, J., Chondrocyte death in experimental osteoarthritis is mediated by MEK 1/2 and p38 pathways: role of cyclooxygenase-2 and inducible nitric oxide synthase.J. Rheumatol., 11, 2509–2519 (2001).Google Scholar
- Rodan, G. A. and Noda, M., Gene expression in osteoblastic cells.Crit. Rev. Eukaryot. GeneExpr., 1, 85–98 (1991).Google Scholar
- Wang, E. A., Rosen, V., DAIessandro, J. S., Bauduy, M., Cordes, P., Harada, T., Israel, D. I., Hewick, R. M., Kerns, K. M., LaPan, P., Luxenberg, D. P., McQuaid, D., Moutsatsos, K. I., Nove, J., and Wozney, J. M., Recombinant human bone morphogenetic protein induces bone formation.Proc. Natl. Acad. Sci. U.S.A., 87, 2220–2224 (1990).PubMedCrossRefGoogle Scholar
- Yamaguchi, A., Katagiri, T., Ikeda, T., Wozney, J. M., Rosen, V., Wang, E. A., Kahn, A. J., Suda, T., and Yoshiki, S., Recombinant human bone morphogenetic protein-2 stimulates osteoblastic maturation and inhibits myogenic differentiationin vitro.J. Cell Biol., 113, 681–687 (1991).PubMedCrossRefGoogle Scholar